This makes transient AKT-inhibition an interesting approach to improve adoptive T cell products, including ex vivo expanded tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-transduced T cells [9, 12, 14, 15]. This evidence concerns the gene AKT1 and neoplasm.